Blogs

A pipeline of encouraging funding opportunities for the engineering biology community

The challenges businesses must address to mitigate risk and ensure seamless compliance

New AI infrastructure, the MHRA AI Sandbox, life science leadership, global advocacy and BIA’s upcoming events

The challenge of converting scientific progress into real-world access

How finance leaders can manage R&D tax risk while supporting innovation investment

Chris Molloy on building on Parliament Day's momentum, TechBio's breakthrough week, the Oxford-to-Cambridge expansion, and driving global investor confidence at the Leadership Summit

Driven by world-class science and monumental funding, the UK TechBio sector is undergoing a profound paradigm shift –​​​​​​​​​​​ meet the innovative BIA members leading the charge

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

BIA members gathered in London on Tuesday for our 26th annual Parliament Day

Chris Molloy on Parliament Day, the EU start-up fund, MHRA rare disease regulation, Northern Ireland, women in biotech and scientific leadership

Overcoming regulatory hurdles to secure the UK’s place in the global engineering biology race

Fundraising, collaboration, IP and leadership in focus as founders and investors shared practical advice for scaling in the UK

Chris Molloy discusses Government engagement, the King’s Speech, health data, Isomorphic’s huge raise, the Start-up Festival and expanding BIA’s reach

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament

Four of the most significant opportunities currently available to engage with global industry leaders

BIA CEO Chris Molloy discusses the vision for data report, rare disease R&D, Women in Biotech, Europe GMO rules, Bio€quity and Swiss Biotech Day

In this guest blog, Catherine Hsu Steve Cardosi discuss Convertible Loan Notes (CLNs).

In this guest blog, Asma Aslam says that rising domestic costs and strong overseas capabilities are pushing companies to subcontract abroad.

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.